GlassScriptPhysician profile
Barbara B O'Callaghan
NPI 1003041104
$6,131.16
in general payments reported to CMS, 2019-2025
51 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 95% of Oncology (Registered Nurse) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $926 · 2023: $2,011 · 2024: $1,615 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $773.81 | 2023-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $456.74 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $319.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $306.25 | 2021-2025 | Enhertu, Lynparza, Calquence |
| Seagen INC. | $297.06 | 2021-2023 | Adcetris, Tukysa, Tivdak |
| Janssen Biotech, INC. | $263.79 | 2022-2024 | Darzalex, Imbruvica, Talvey |
| Pfizer INC. | $253.07 | 2021-2025 | |
| Daiichi Sankyo INC. | $245.94 | 2021-2025 | Enhertu, Datroway |
| Abbvie INC. | $243.70 | 2023-2025 | |
| Celgene Corporation | $232.65 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $204.69 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $178.62 | 2022-2024 | |
| Glaxosmithkline, LLC. | $158.47 | 2021-2025 | Ojjaara, Jemperli, Shingrix |
| Genzyme Corporation | $141.13 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $120.97 | 2023-2025 | Qinlock, Tgct, Romvimza |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $119.01 | 2021-2025 | Venclexta, Polivy, Tecentriq |
| Stemline Therapeutics INC. | $116.13 | 2023-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $106.19 | 2022-2024 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $105.46 | 2022-2023 | Imbruvica, Epkinly |
| Coherus Oncology, INC. | $102.30 | 2022-2025 | Loqtorzi |
| Amgen INC. | $93.74 | 2021-2023 | Kyprolis, Lumakras, Vectibix |
| Bayer Healthcare Pharmaceuticals INC. | $93.62 | 2022-2025 | |
| Beigene USA, INC. | $88.51 | 2023-2024 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $76.96 | 2023-2024 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $71.18 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.53 | 2023 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $62.73 | 2021-2023 | Libtayo |
| Sobi, INC | $60.46 | 2025 | |
| Jazz Pharmaceuticals INC. | $60.26 | 2024-2025 | |
| Tempus Ai, INC | $56.85 | 2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $55.15 | 2023-2024 | |
| Mirati Therapeutics, INC. | $51.81 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $47.31 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $47.27 | 2022-2024 | Ultomiris |
| Array Biopharma INC | $45.81 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Adc Therapeutics America, INC. | $41.47 | 2023-2024 | |
| Gilead Sciences, INC. | $38.47 | 2022-2024 | |
| Tersera Therapeutics LLC | $38.14 | 2021-2024 | Zoladex |
| Lilly USA, LLC | $31.29 | 2024 | Jaypirca |
| Aveo Pharmaceuticals, INC. | $30.48 | 2024 | |
| Inari Medical, INC. | $30.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astellas Pharma US INC | $24.22 | 2023 | |
| Janssen Pharmaceuticals, INC | $24.14 | 2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $22.77 | 2022 | |
| Legend Biotech USA INC. | $21.93 | 2025 | Carvykti |
| Myovant Sciences INC. | $21.64 | 2021 | |
| Foundation Medicine, INC. | $19.96 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.93 | 2021 | |
| Morphosys, US INC. | $16.25 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.71 | 2022 | |
| Beone Medicines USA, INC. | $14.07 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara O'Callaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.